Efficacy and safety of a novel oral isoxazoline, sarolaner (Simparica™) in the treatment of naturally occurring flea and tick infestations in dogs presented as veterinary patients in Europe  by Becskei, Csilla et al.
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a  b  s  t  r  a  c  t
Two  randomised,  blinded,  multi-centered  ﬁeld  studies  were conducted  in  Europe  to  demonstrate  the
efﬁcacy  and  safety  of three  monthly  oral  doses  of  sarolaner  (SimparicaTM, Zoetis)  administered  at  a min-
imum  dosage  of  2.0  mg/kg  (range  2–4  mg/kg)  against  natural  ﬂea or  tick  infestation  of  dogs  presented
as  veterinary  patients.  In the  ﬂea  study,  the improvement  in clinical  signs  associated  with  ﬂea allergy
dermatitis  (FAD)  was  also  investigated.  The  palatability  of the  sarolaner  chewable  tablet  formulation
was  evaluated  in both  studies.  Spinosad  (Comfortis® Chewable  Tablets,  Elanco)  and  ﬁpronil  (Frontline®
Spot  on,  Merial)  were  used  as positive  controls  in  the ﬂea  and  tick  study,  respectively.  Treatments  were
administered  on  Days  0,  30 and  60.  Efﬁcacy  was  calculated  based  on the  mean  percent  reduction  of  live
parasite  counts  on  post-treatment  days  14, 30, 60 and  90 versus  the  pre-treatment  count on  Day  0.  Non-
inferiority  of  sarolaner  to  the  control  products  was assessed  at each  time-point  using  a margin  of 15% at
the  one-sided  0.025 signiﬁcance  level.
Dogs were  enrolled  in  a 2:1  ratio  (sarolaner:comparator);  285  ﬂea-  and  181  tick-infested  dogs  were
assessed  for  efﬁcacy  and  safety,  and  137  and  48  dogs  were  assessed  for safety  only,  in the  ﬂea  and  tick
study,  respectively.  There  were  no  treatment-related  adverse  events.
Efﬁcacy against  ﬂeas  was  98.8%,  99.4%,  >99.9%  and  >99.9%  in the sarolaner-treated  group  and  98.9%,
93.7%,  96.8%  and  95.1%  in the  spinosad-treated  group  on  Days  14,  30,  60 and  90,  respectively.  Sarolaner
was  non-inferior  to spinosad  at all time-points  and  was  superior  on  Day  30. For the 42 dogs  identiﬁed  as
having  FAD  at  enrolment,  the  clinical  signs  of FAD  improved  in  all dogs  and  the  incidence  was  markedly
reduced  by the  end of  the  study.
Efﬁcacy  against  ticks  was  97.4%,  97.6%,  99.8%  and  100%  in  the  sarolaner-treated  group  and  94.1%,
88.5%,  89.9%  and  98.1%  in  the  ﬁpronil-treated  group  on Days  14, 30,  60  and  90,  respectively.  Sarolaner
was  non-inferior  to  ﬁpronil  at all time-points,  and  was superior  on  Days  30 and  60.  Sarolaner  tablets
were  voluntarily  and  fully  consumed  within  one  minute  in  93%  of  the  1280  occasions  offered.
Sarolaner  administered  orally  at monthly  intervals  at a minimum  dosage  of  2  mg/kg  was  safe  and  highly
effective  against  natural  infestations  of ﬂeas  and  ticks on  dogs.  In  addition,  clinical  signs  FAD improved
in  dogs  treated  with  sarolaner,  and  the ﬂavored,  chewable  tablets  were  highly  palatable.
©  2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. IntroductionTreatment and prevention of ectoparasite infestations on com-
anion animals is an integral part of general veterinary practice
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around the world. It has been reported that ﬂea infestations account
for over 50% of the dermatological cases presented to veterinarians
and dealing with ﬂea infestations comprises 35% of their total case
load (Bevier-Tournay, 1989; Kwochka, 1987). In recent studies, the
prevalence of ﬂea infestations in canine veterinary patients was
found to be up to 27.1% in Hungary, 40.3% in Greece, 17.9% in Italy
and 30.3% in Mexico (Koutinas et al., 1995; Cruz-Vazquez et al.,
2001; Rinaldi et al., 2007; Farkas et al., 2009). The economic impact
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Table 1
Demographic characteristics of dogs presented as veterinary patients and dosed
with sarolaner or spinosad tablets administered orally, or treated with ﬁpronil top-
ically once a month for three months.
Tick study Flea study
Sarolaner Fipronil Sarolaner Spinosad
Number of dogs enrolled 150 79 287 141
Purebred 68.0% 62.0% 65.9% 64.5%
Non-purebred 32.0% 38.0% 34.1% 35.5%
Live indoors and outdoors 47.3% 49.4% 33.4% 38.3%
Live mostly indoors 4.7% 3.8% 12.5% 5.7%
Live  mostly outdoors 48.0% 46.8% 54.0% 56.0%
Male 46.7% 50.6% 46.7% 52.5%
Female 53.3% 49.4% 53.3% 47.5%
Long hair 20.7% 27.8% 15.3% 14.2%
Medium length hair 41.3% 38.0% 41.5% 48.2%
Short hair 38.0% 34.2% 43.2% 37.6%
Receiving concurrent medication* 5.3% 7.6% 5.2% 6.4%
Not  receiving concurrent medication 94.7% 92.4% 94.8% 93.6%
*In the sarolaner-treated group dogs were receiving the following concurrent med-
ication at enrolment: doxycycline, meloxicam, vaccines, ﬁrocoxib, dexamethasone,
benzylpenicillin, dihydrostreptomycin sulfate, moxidectin, ivermectin, carpro-
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ven, benazepril, amoxicillin in combination with clavulanic acid, medetomidine,
ephalexine, pyrantel + ivermectin, spiramycine + metronidazole, phenobarbital,
entosan polysulphate.
f ﬂea treatments is also high; it has been estimated globally that
et owners spend more than 2 billion USD annually on ﬂea products
lone (Conniff, 1995; Krämer and Mencke, 2001; Rust 2005).
Tick infestations are similarly a common problem in dogs. The
edian frequency of dogs carrying ticks in Great Britain was found
o be 14.9% (Smith et al., 2011). Ticks are one of the most impor-
ant vectors of diseases caused by pathogenic protozoa (e.g. Babesia
pp.), viruses (e.g. tick-borne encephalitis virus), rickettsia, and bac-
eria (e.g. Borrelia burgdorferi s.l., Ehrlichia spp., Francisella tularensis,
naplasma spp.) in dogs, many of which are zoonotic.
Due to the prevalence of ﬂea and tick infestations and the poten-
ial severity of tick-borne diseases there is high need for safe and
fﬁcacious products to treat ﬂea and tick infestations on dogs.
arolaner (SimparicaTM) is the latest addition to the isoxazoline
lass of oral ectoparasiticides. Two clinical ﬁeld studies were con-
ucted in Europe to evaluate its efﬁcacy and safety against natural
ea and tick infestations in canine veterinary patients.. Materials and methods
Two randomised, blinded, positive-controlled clinical ﬁeld stud-
es were conducted at veterinary clinics in Belgium, Hungary, Italy,
able 2
fﬁcacy against ﬂeas: Number of dogs, arithmetic mean live ﬂea counts (all species), ran
eterinary patients and dosed with sarolaner or spinosad tablets administered orally onc
Study Day Treatment group Number of dogs Flea counts 
Arithmetic mean
−1 to 0 Sarolaner 189 23.1 
Spinosad 95 18.7 
14  ± 3 Sarolaner 184 0.2 
Spinosad 88 0.2 
30  ± 3 Sarolaner 186 0.1 
Spinosad 89 1.3 
60  ± 3 Sarolaner 186 <0.1 
Spinosad 87 0.3 
90  ± 3 Sarolaner 182 <0.1 
Spinosad 92 0.4 
a Efﬁcacy is the arithmetic mean of the percent reduction relative to pre-treatment calsitology 222 (2016) 49–55
France and the United Kingdom enrolling dogs presenting with ﬂea
and/or tick infestations. All personnel (e.g., the Examining Veteri-
narian) involved with the collection of efﬁcacy and safety data were
blinded to treatment All treatments were dispensed to the Owners
by separate study personnel (Dispenser), who were not involved in
any other study activities. The studies were conducted in compli-
ance with Good Clinical Practice, (VICH guideline GL9, EMEA, 2000)
and the study protocols were reviewed and approved by the Zoetis
Ethics Review Assessment team.
2.1. Animals
Enrolment was limited to households with three or fewer dogs.
One dog in each household was allowed to be enrolled as the pri-
mary patient and only that dog received efﬁcacy evaluations. Other
dogs living in the same household as the primary dog were enrolled
as supplementary patients and received the same treatment but
were only evaluated for safety and palatability, not for efﬁcacy. The
primary patient had to harbor ≥5 live ﬂeas or ≥3 live attached ticks
at enrolment. Within each clinic the primary dogs were randomly
allocated to the two  treatment groups (separately in each study) in
a ratio of 2:1, so that for every two patients that received sarolaner,
one patient received the positive control product (spinosad in the
ﬂea study and ﬁpronil in the tick study). Supplementary dogs in the
ﬂea study had to be enrolled and treated, while in the tick study, the
enrolment and treatment of the supplementary dogs was  optional
for the Owners. Dogs that were pregnant, lactating or intended for
breeding were excluded from the studies. All dogs received a physi-
cal examination by a veterinarian at study inclusion. The minimum
age for enrolment was  eight weeks in the tick study and 14 weeks
(due to the age restrictions of the comparator product) in the ﬂea
study. Each dog was  enrolled with the written informed consent of
its owner.
2.2. Treatment administration
Dogs received three consecutive monthly treatments on study
days 0, 30 and 60. For the follow up treatments and evaluations
on Days 30 and 60 these could be conducted ± 3 days of the tar-
get date, but these are reported as Days 30 and 60. All treatments
were dispensed according to a randomization plan that was pro-
vided for each clinic before study start. Treatment dispensing was
based upon the body weights recorded on Day 0, 30 and 60, and
treatments were administered by the Owner in the home envi-
ronment after the clinic visits. The dogs’ owners were not blinded
to treatment allocation. Animals were dosed with the appropri-
ate strength sarolaner tablet (SimparicaTM, Zoetis) to provide the
ges and percent efﬁcacies relative to pre-treatment counts for dogs presented as
e a month for three months.
Efﬁcacya (%)
 Range Arithmetic mean 95% Conﬁdence interval
5 to 1029 – –
5 to 173 N/A –
0 to 10 98.8 97.8 − 99.8
0 to 4 98.9 98.1 − 99.8
0 to 8 99.4 98.8 − 99.9
0 to 38 93.7 89.0 − 98.6
0 to 1 >99.9 99.7 − 100.1
0 to 17 96.8 91.3 − 102.7
0 to 1 >99.9 99.7 − 100.1
0 to 19 95.1 87.0 − 103.3
culated for each dog individually.
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Table  3
Statistical comparison of ﬂea efﬁcacy (all species) for dogs presented as veterinary
patients and dosed with sarolaner or spinosad tablets administered orally once a
month for three months.
Study Day Difference 95% Conﬁdence interval Non-Inferior?a Superior?
14 ± 3 −0.1 −1.4 to 1.2 Yes No
30  ± 3 5.6 0.8 to 10.4 Yes Yesb
60 ± 3 2.9 −2.8 to 8.6 Yes No
90  ± 3 4.7 −3.4 to 12.9 Yes No
a sarolaner is non-inferior to spinosad at 2.5% alpha if the lower limit of the 95%
conﬁdence interval is greater than −15.
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superior to the positive control product.
T
N
aOn Day 30 ± 3 the lower limit of the 95% conﬁdence interval is greater than 0,
ndicating superiority of sarolaner over spinosad.
ecommended minimum dosage of 2 mg/kg (range 2–4 mg/kg). In
he ﬂea study the positive control product (Comfortis® Chewable
ablets; Elanco) was dosed following manufacturer’s recommenda-
ions to deliver 45–70 mg/kg spinosad. In the tick study the positive
ontrol product (Frontline® Spot on, Merial) was  dosed following
anufacturer’s recommendations to deliver 7.5–15 mg/kg ﬁpronil
nd it was applied topically, directly to the skin. There were no
estrictions regarding the prandial state at the time of sarolaner
dministration, therefore tablets could be administered with or
ithout food. Spinosad was administered with the main meal of
he dog in order to comply with the approved dosing directions for
hat product.
.3. Efﬁcacy assessment
Parasite counts on primary dogs were conducted prior to treat-
ent on Day 0, and on post-treatment Days 14, 30, 60 and 90
the post-treatment evaluations could be conducted ± 3 days of the
arget day). Dogs were thoroughly examined (and combed using
ea combs) for at least 10 min  by blinded study personnel (e.g.,
xamining Veterinarian or Technician) until all ﬂeas and/or ticks
ere removed. The collected parasites were counted and stored in
lcohol solution (at least 70%) at room temperature. The species
nd gender of the ﬂeas, and the species, developmental status and
ender of the adult ticks collected from the primary dogs were
etermined at a single central parasitology laboratory (Faculty
f Veterinary Science, Budapest) under a stereomicroscope using
dentiﬁcation keys (Szabó, 1975; Hillyard, 1996; Estrada-Pena et al.,
004). Engorgement status of the ticks was determined by visual
nspection of the alloscutum.
In the ﬂea study, each primary dog was also thoroughly exam-
ned for clinical signs of ﬂea allergy dermatitis (FAD) including but
ot limited to pruritus, erythema, scaling, alopecia, and dermati-
is/pyodermatitis, prior to treatment on Day 0, and on Days 14,
0, 60 and 90. The Examining Veterinarian assessed the severity of
able 4
umbers of dogs infested with the cat ﬂea (Ctenocephalides felis) or with the dog ﬂea (Cten
s  veterinary patients and dosed with sarolaner or spinosad tablets administered orally o
C. felis 
Treatment group Study day Dogs Dogs with ﬂeas (%) M
Sarolaner −1 to 0 189 142 (75.1) 1
14  ± 3 184 7 (3.8) 5
30  ± 3 186 8 (4.3) 8
60  ± 3 186 1 (0.5) 1
90  ± 3 182 1 (0.5) 1
Spinosad −1 to 0 95 72 (75.8) 1
14  ± 3 88 9 (10.2) 4
30  ± 3 89 10 (11.2) 3
60  ± 3 87 2 (2.3) 1
90  ± 3 92 4 (4.3) 1sitology 222 (2016) 49–55 51
the clinical signs on a four level scale as absent, mild, moderate or
severe.
2.4. Safety assessment
All dogs (primary and supplementary) that received at least
one treatment were included in the safety assessment. All dogs
received a physical examination by the veterinarian prior to treat-
ment on Day 0, and on Days 30, 60 and 90. Primary dogs received
an additional physical examination by the veterinarian on Day 14.
All abnormal health events observed during the physical examina-
tions by the veterinarian or observed by the owner between visits,
were recorded.
2.5. Palatability assessment
The voluntary acceptance and consumption of tablets was eval-
uated by the dog’s owner at each administration for all orally-dosed
dogs. The dogs were allowed one minute to accept and consume
the offered tablets for the palatability assessment. Tablets or tablet
fragments that were not voluntarily consumed within this period
were administered in food or by pilling to ensure complete dosing.
2.6. Data analysis
The animal (primary dog per household) was  the experimental
unit. Efﬁcacy was  calculated at each post-treatment visit day (Day
14, 30, 60 and 90) as the percentage reduction in live parasite counts
compared to the pre-treatment counts (recorded on Day 0) for each
animal using the following formula:
%efﬁcacy post − treatment =
100 × count (Day0) − count (post − treatment)
count (Day0)
Efﬁcacy was calculated across all ﬂea and tick species in the ﬂea
and tick study, respectively. Additionally, efﬁcacy was calculated
for each ﬂea and tick species separately if at least ﬁve dogs in each
treatment group had parasites of a given species at enrolment.
Statistical comparison of efﬁcacy between sarolaner and the
positive control product was done by non-inferiority analysis at
each visit using a margin of 15% at the one-sided,  = 0.025 signiﬁ-
cance level. If the lower limit of the 95% conﬁdence interval of the
difference in efﬁcacy between sarolaner and the positive control
product was  greater than −15% then sarolaner was  non-inferior to
the positive control product at that time point. If the lower limit
of the 95% conﬁdence interval was greater than 0, sarolaner wasThe improvement in clinical signs of FAD was  assessed for pri-
mary dogs that were identiﬁed by the Examining Veterinarian as
having FAD. The numbers and percentages of dogs with each of
ocephalides canis), and the maximum ﬂea count for each species for dogs presented
nce a month for three months.
C. canis
aximum ﬂea count Dogs with ﬂeas (%) Maximum ﬂea count
316 50 (26.5) 249
 6 (3.3) 10
 1 (0.5) 1
 1 (0.5) 1
 1 (0.5) 1
51 24 (25.3) 102
 1 (1.1) 1
9 4 (4.4) 17
7 1 (1.1) 1
9 0 (0.0) 0
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Table 5
Clinical signs of ﬂea allergy dermatitis: Number and percent of dogs with clinical signs at enrolment and at study completion for dogs presented as veterinary patients and
dosed  with sarolaner or spinosad tablets administered orally once a month for three months.
Clinical Sign Sarolaner Spinosad
Enrolment n = 30 Completion n = 27 Enrolment n = 12 Completion n = 12
n % n % n % n %
Alopecia 20 66.7 1 3.7 12 100 1 8.3
Dermatitis/Pyodermatitis 24 80.0 1 3.7 6 50.0 1 8.3
Erythema 25 83.3 0 0.0 11 91.7 0 0.0
Pruritus 29 96.7 2 7.4 12 100 0 0.0
Scaling 21 70.0 2 7.4 9 75.0 0 0.0
Table 6
Efﬁcacy against ticks: Number of dogs, arithmetic mean live tick counts (all species), ranges and percent efﬁcacies relative to pre-treatment counts for dogs presented as
veterinary patients and dosed with sarolaner administered orally or treated with ﬁpronil topically once a month for three months.
Study Day Treatment group Number of dogs Tick counts Efﬁcacya (%)
Arithmetic mean Range Arithmetic mean 95% Conﬁdence interval
−1 to 0 Sarolaner 121 12.5 3 to 516 – –
Fipronil 59 10.9 3 to 81 – –
14  ± 3 Sarolaner 119 0.2 0 to 10 97.4 94.8– 100.1
Fipronil 58 1.6 0 to 34 94.1 90.3–97.9
30  ± 3 Sarolaner 118 0.4 0 to 32 97.6 93.4– 101.9
Fipronil 57 2.5 0 to 53 88.5 81.9–94.1
60  ± 3 Sarolaner 119 0.0 0 to 2 99.8 96.1–103.5
Fipronil 54 4.4 0 to 146 89.9 84.3–95.2
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ﬁ90  ± 3 Sarolaner 117 0.0 
Fipronil 54 0.4 
a Efﬁcacy is the arithmetic mean of the percent reduction relative to pretreatmen
he clinical signs of FAD were calculated by severity category. Dogs
hat received concomitant medications that could have potentially
ffected the clinical signs of FAD were excluded from this analysis.
o assess palatability, the percent of treatment administrations in
hich the whole prescribed dose was consumed voluntarily within
ne minute was calculated.
. Results
.1. Animals
In the ﬂea study, 285 primary (189 sarolaner- and 96
pinosad-treated) and 137 supplementary (93 sarolaner- and 44
pinosad-treated) dogs were enrolled and treated. Dogs in the
arolaner group had a mean age of 5.5 years (range 14 weeks to
5 years) and mean weight of 19.6 kg (range 3.9–60.0 kg). Dogs in
he spinosad group had a mean age of 5.7 years (range 14 weeks
o 15 years) and mean weight of 18.8 kg (range 4.0–65.2 kg). Seven
ogs in the sarolaner group and 4 dogs in the spinosad group did not
omplete the study. In the sarolaner group one dog was  withdrawn
ecause of suspected pregnancy, one primary dogs run away from
ome triggering the withdrawal of the 2 supplementary dogs living
n the same household, one supplementary dog was hit by car and
ied, one supplementary dog was withdrawn due to concomitant
isease (acute peritonitis due to pyometra) and one dog was with-
rawn because of Owner non-compliance. In the spinosad-treated
roup one supplementary dog was withdrawn due to concomitant
isease (pyometra), two dogs because of Owner non-compliance
nd one primary dog because the supplementary dog did not meet
nclusion criteria. Thus 279 primary patients (186 sarolaner- and 93
pinosad-treated) and 132 supplementary patients (89 sarolaner-
nd 43 spinosad-treated) completed the ﬂea study.
In the tick study, 181 primary (122 sarolaner- and 59
pronil-treated) and 48 supplementary (28 sarolaner- and 20
pronil-treated) dogs were enrolled and treated. Dogs in the0 100 98.7–101.2
0 to 10 98.1 96.2–99.9
ulated for each dog individually.
sarolaner group had a mean age of 4.9 years (range 10 weeks to
14 years) and mean weight of 22.2 kg (range 2.9–66.5 kg). Dogs in
the ﬁpronil-treated group had a mean age of 4.9 years (range 10
weeks to 17 years) and mean weight of 21.7 kg (range 4.5–53.0 kg).
Four dogs in each group did not complete the study. During the
study one dog in the sarolaner group was withdrawn because
of suspected pregnancy, two dogs run away from home and one
supplementary dog was withdrawn because it was added to the
household after enrolment of primary dog. In the ﬁpronil-treated
group one dog was withdrawn because of lack of efﬁcacy, one due
to concomitant disease (babesiosis) and two dogs because of Owner
non-compliance. Thus 175 primary patients (119 sarolaner- and 56
ﬁpronil-treated) and 46 supplementary patients (27 sarolaner- and
19 ﬁpronil-treated) completed the tick study.
The demographic characteristics of the dogs at enrolment were
similar in both treatment groups in both studies (Table 1).
3.2. Flea efﬁcacy
3.2.1. Overall ﬂea efﬁcacy
The results for all ﬂea species combined are summarized in
Table 2. Arithmetic mean of live ﬂea counts at enrolment were
23.1 (range 5–1,029) in the sarolaner-treated group and 18.7 (range
5–173) in the spinosad-treated group. On post-treatment Days 14,
30, 60 and 90, efﬁcacy was 98.8, 99.4, >99.9 and >99.9%, respec-
tively in the sarolaner-treated group, and 98.9, 93.7, 96.8 and 95.1%,
respectively in the spinosad-treated group. Only single ﬂeas were
recovered from sarolaner-treated dogs on Days 60 and 90, while
at the same time points, individual dogs in the spinosad-treated
group harbored up to 17 and 19 ﬂeas, respectively. Sarolaner was
non-inferior to spinosad at all time-points and was superior on Day
30 (Table 3).
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Table  7
Statistical comparison of tick efﬁcacy (all species) for dogs presented as veterinary
patients and dosed with sarolaner tablets administered orally or treated with ﬁpronil
topically once a month for three months.
Study Day Difference 95% Conﬁdence interval Non-Inferior?a Superior?
14 ± 3 3.4 −1.2 to 8.0 Yes No
30  ± 3 9.7 2.3 to 17.1 Yes Yesb
60 ± 3 10.0 3.5 to 16.6 Yes Yesb
90 ± 3 1.9 −0.3 to 4.2 Yes No
a Sarolaner is non-inferior to ﬁpronil at 2.5% alpha if the lower limit of the 95%
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b On Day 30 ± 3 and 60 ± 3 the lower limit of the 95% conﬁdence interval is greater
han 0, indicating superiority of sarolaner over ﬁpronil.
.2.2. Flea species
At enrolment 214 dogs (75.1%) were infested with Cteno-
ephalides felis (cat ﬂea) and 74 dogs (26.0%) with Ctenocephalides
anis (dog ﬂea). Other ﬂeas identiﬁed from less than ﬁve dogs at
nrolment were a single Nosopsyllus fasciatus (northern rat ﬂea) and
wo damaged ﬂeas collected from two dogs could only be identiﬁed
o the genus Ctenocephalides. The numbers and proportions of dogs
nfested with C. felis and C. canis and the maximum ﬂea counts for
ach species are summarized in Table 4.
For C. felis, treatment with sarolaner resulted in a large decrease
n the incidence of infestations with greater than 95% of dogs being
ea-free on all post-treatment time-points, the maximum number
f ﬂeas recovered from any dog was eight on Day 30, and only single
eas were found on Days 60 and 90. Incidence of infestation with
. felis was higher for spinosad-treated dogs with over 10% of dogs
aving up to four or 39 ﬂeas on Days 14 and 30, respectively (<90%
f dogs were ﬂea–free), and 2.3% and 4.3% of dogs with up to 17 and
9 ﬂeas on Days 60 and 90, respectively.
For C. canis, the incidence of infestation in sarolaner-treated
ogs also dropped sharply with only a single dog with a single ﬂea
ound from Day 30 onward. A similar reduction in the incidence of
. canis infestation was observed in dogs treated with spinosad.
.2.3. Flea allergy dermatitis
Thirty primary dogs in the sarolaner-treated group and 12
n the spinosad-treated group were identiﬁed as having FAD at
nrolment. The clinical signs of ﬂea allergy dermatitis (alope-
ia, dermatitis/pyodermatitis, erythema, pruritus and scaling)
mproved in all dogs following treatment administration in both
roups (Table 5). At enrolment, incidence of any one of the clinical
igns of FAD ranged from 50% to 100%; by the end of the study, the
ncidence of these signs had declined to 0–8.3% in both groups.
.3. Tick efﬁcacy
.3.1. Overall tick efﬁcacy
The efﬁcacy against all tick species combined is summarized in
able 6. Arithmetic mean live tick counts at enrolment were 12.5
range 3–516) in the sarolaner-treated group and 10.9 (range 3–78)
n the ﬁpronil-treated group. Efﬁcacy on post-treatment Days 14,
0, 60 and 90 was 97.4, 97.6, 99.8 and 100% in the sarolaner-treated
roup, and 94.1, 88.5, 89.9 and 98.1 in the ﬁpronil group. Sarolaner
as determined to be non-inferior to ﬁpronil at all time-points, and
uperior to ﬁpronil on Days 30 and 60 (Table 7).
.3.2. Tick species
At enrolment 95 dogs (52.8%) were infested with Ixodes ricinus,
4 (41.1%) with Rhipicephalus sanguineus, 43 (23.9%) with Derma-
entor reticulatus and 12 (6.7%) with Ixodes hexagonus.  Some dogs
arbored mixed infestations of more than one tick species. The
umbers and proportions of dogs infested with any of the four tick
pecies and the maximum tick counts for each species are summa-sitology 222 (2016) 49–55 53
rized in Table 8. Overall the initial incidence of each species was
similar for each treatment group. A small number of damaged ticks
were recovered from a few dogs during the study which could not
be identiﬁed.
Treatment with sarolaner resulted in a large decrease in the inci-
dence of infestations for all tick species by Day 14 (efﬁcacy was
97.4% for I. ricinus,  99.7% for I. hexagonus,  97.9% for R. sanguineus and
100% for D. reticulatus). Tick infestations declined further at subse-
quent exams and all dogs were tick free by Day 90. Interestingly,
while I. hexagonus had the lowest incidence on dogs at enrolment
(5.0%), this species had the highest numbers of ticks infesting indi-
vidual dogs (516 on one dog allocated to the sarolaner group). Ten
and 32 I. hexagonus were collected from single sarolaner-treated
dogs on Days 14 and 30, respectively, but none were found on Days
60 and 90. The ﬁpronil-treated dogs also showed a reduction in all
four tick species but for the majority of species, this reduction was
markedly lower than for sarolaner and even after three treatments,
three of the four tick species were found on one or two dogs. In con-
trast to the sarolaner-treated dogs, the dogs that harbored ticks in
the ﬁpronil-treated group tended to have high numbers of live ticks.
This was most notable for I. ricinus where ﬁpronil-treated dogs were
infested with up to 53 and 59 ticks on Days 30 and 60, respectively,
which was similar to the pre-treatment maximum of 64 ticks. This
was also the case for I. hexagonus,  where ﬁpronil-treated dogs were
infested with up to 145 ticks on Day 60, which was higher than the
pre-treatment maximum of 77 ticks (Table 8).
3.4. Safety
There were no treatment-related adverse events in sarolaner-
treated dogs. The overall incidence of adverse events was  low. These
occurred in 19 sarolaner-treated dogs (4.3%), in 9 spinosad-treated
(6.4%) and 2 ﬁpronil-treated dogs (2.5%). The majority of observed
clinical signs were sporadic occurrences of conditions commonly
observed in the general dog population. Dermatological conditions
were the only adverse events that occurred in >1.0% of sarolaner-
treated dogs in either study. These observations included single
dogs diagnosed with a hot-spot on study Day 19, a bacterial skin
infection on Day 9, skin necrosis following FAD on Day 8, an inter-
digital pyoderma on Day 38, an unidentiﬁed lump on the skin on
Day 40 and alopecia of suspected endocrine origin on Day 8. Severe
adverse events occurred in three dogs: in the sarolaner group, one
dog died as a result of septicaemia, and one as a result of acute
peritonitis secondary to pyometra; in the spinosad group, one dog
developed pyometra and was euthanized. These abnormal health
events were considered unlikely to be related to treatment admin-
istration.
3.5. Palatability
In the two  studies, sarolaner chewable tablets were voluntarily
and fully consumed within one minute on 93% of the 1280 occasions
they were offered without food. Spinosad chewable tablets were
voluntarily and fully consumed within one minute on 84.2% of the
411 occasions offered.
4. Discussion
Sarolaner (SimparicaTM) administered orally at the recom-
mended minimum dosage of 2 mg/kg at monthly intervals was safe
and highly effective against natural ﬂea and tick infestations of
dogs. The efﬁcacy of sarolaner against ﬂeas was superior to the
commercial comparator spinosad at the end of the ﬁrst treatment
period (Day 30) and non-inferior at all other time points. Similarly,
sarolaner had superior efﬁcacy against ticks compared to ﬁpronil
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Table 8
Numbers of dogs infested with the ticks, Ixodes ricinus, Rhipicephalus sanguineus, Dermacentor reticulatus or Ixodes. hexagonus, and the maximum tick count for each species
for  dogs presented as veterinary patients and dosed with sarolaner administered orally or treated with ﬁpronil topically once a month for three months.
I. ricinus R. sanguineus D. reticulatus I. hexagonus
Treatment group Study day Dogs Dogs with
ticks (%)
Max. tick
count
Dogs with
ticks (%)
Max. tick
count
Dogs with
ticks (%)
Max. tick
count
Dogs with
ticks (%)
Max. tick
count
Sarolaner −1 to 0 121 66 (54.5) 43 49 (40.5) 63 31 (25.6) 7 6 (5.0) 516
14  ± 3 119 3 (2.5) 5 2 (1.7) 5 1 (0.8) 4 1 (0.8) 10
30  ± 3 118 2 (1.7) 2 2 (1.7) 10 1 (0.8) 1 1 (0.8) 32
60  ± 3 119 0 (0.0) 0 1 (0.8) 1 0 (0.0) 0 0 (0.0) 0
90  ± 3 117 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
Fipronil −1  to 0 59 29 (49.2) 64 25 (42.4) 81 12 (20.3) 10 6 (10.2) 77
14  ± 3 58 3 (5.2) 34 4 (6.9) 5 1 (1.7) 3 3 (5.2) 14
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t the end of the ﬁrst and second treatment periods (Days 30 and
0) and was non-inferior on Day 90.
Under ﬁeld conditions, dogs are continuously exposed to re-
nfestations by ﬂeas and ticks from the environment. Therefore,
ctoparasiticides should not only provide rapid immediate efﬁcacy,
ut also sustained persistent efﬁcacy after a single administration
ntil the end of the treatment period to protect the dogs from
e-infestation. Sarolaner provided >99% and >97% efﬁcacy against
eas and ticks, respectively, at 30 days after the ﬁrst administra-
ion and this efﬁcacy was  superior to both spinosad and ﬁpronil.
his sustained efﬁcacy provided by treatment with sarolaner was
ven higher 30 days after the second and third monthly treatments.
Against ﬂeas, sarolaner provided >99% efﬁcacy at 30 days
fter each monthly treatment. In contrast, spinosad resulted in
nly 93.7% efﬁcacy 30 days after the ﬁrst treatment and efﬁcacy
emained <97% following the two subsequent monthly treatments.
The clinical signs of FAD were markedly reduced through the
ourse of the study in sarolaner-treated dogs, with only a few dogs
xhibiting any signs at the end of the study (Table 5). As no concomi-
ant medications were administered to directly treat these signs,
esolution was a result of the rapid and persistent elimination of
dult ﬂeas provided by sarolaner (Six et al., 2016).
Sarolaner was also highly efﬁcacious against all tick species
ound on the enrolled dogs with efﬁcacy >97% at all assessments
nd which was superior to ﬁpronil at Days 30 and 60. In particular,
arolaner’s efﬁcacy against D. reticulatus during the study period is
f interest, as this species is the main vector of Babesia canis that
an cause lethal disease in dogs. Sarolaner also provided high efﬁ-
acy against I. hexagonus,  and I. ricinus the latter being the most
revalent tick infesting dogs in Europe and the main vectors of B.
urgdorferi s. l. causing Lyme disease in dogs and people. At 30 days
fter the second treatment, neither of these species was found on
ny sarolaner-treated dogs and no live ticks at all were found after
he third treatment. In contrast, at these time-points, ﬁpronil had
elatively poor efﬁcacy against both Ixodes species, with up to 145 I.
exagonus recovered from almost 6% of ﬁronil-treated dogs and up
o 59 I. ricinus recovered from nearly 10% of ﬁpronil-treated dogs
t Day 60, and up to 10 live ticks found on over 6% of dogs after the
hird treatment.
Palatability of sarolaner chewable tablets was evaluated in this
tudy in a large number of dogs of various breeds and sizes.
he overall rate of 93% voluntary full consumption in this study
emonstrates that sarolaner (SimparicaTM) was highly palatable.
n comparison, spinosad (Comfortis®) was voluntarily and fully
onsumed within one minute on 84.2% of all occasions in this
tudy. Another oral ectoparasiticde for dogs containing ﬂuralaner
Bravecto® Merck) was reported to have only 74.4% acceptance
ithin one minute of offerings by owners in the home environment,
.e. under similar conditions as in the current study (Meadows et al.,23 0 (0.0) 0 3 (5.3) 26
10 0 (0.0) 0 3 (5.6) 145
1 0 (0.0) 0 1 (3.7) 8
2014). Sarolaner chewable tablets may  be administered with or
without food. Thus, the high palatability and ease of administration
of sarolaner chewable tablets should enhance owner compliance,
which is a key factor for the success of ectoparasite treatments in
companion animals (Halos et al., 2014).
5. Conclusions
Sarolaner administered orally at monthly intervals at a min-
imum dosage of 2 mg/kg (range 2–4 mg/kg) was safe and highly
effective against natural infestations of ﬂeas and ticks on dogs pre-
sented as veterinary patients. Speciﬁcally under conditions when
dogs were continuously exposed to natural re-infestations with
ticks and ﬂeas, sarolaner provided high efﬁcacy that was sustained
until the end of the monthly dosing interval. Sarolaner improved
the clinical signs of ﬂea allergy dermatitis, due to rapid ﬂea killing
(Six et al., 2016). SimparicaTM Chewable Tablets were highly palat-
able, thus providing a convenient and easy treatment option to
owners for the treatment and control of ﬂea and tick infestations
on dogs.
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